UK 14,275 (Pfizer) an inotropic agent with cardiac phosphodiesterase inhibitory activity, was administered to ten healthy male volunteers. 2. The inotropic activity was assessed by non-invasive measurement of systolic time intervals (STI). 3. The compound had significant inotropic activity in the doses administered, as judged by the shortening of pre-ejection period (PEP), without any significant chronotropic activity. 4. The inotropic effect was abolished when measurements were repeated following beta-adrenoceptor blockade with oral propranolol. 5. The inotropic activity was compared to that of intravenous isoprenaline.
摘要
UK 14,275(辉瑞公司生产)是一种具有心脏磷酸二酯酶抑制活性的强心剂,对10名健康男性志愿者进行了给药。2. 通过无创测量收缩期时间间期(STI)来评估强心活性。3. 从给药剂量来看,该化合物具有显著的强心活性,表现为射血前期(PEP)缩短,且无任何显著的变时活性。4. 口服普萘洛尔进行β-肾上腺素能受体阻滞之后重复测量时,强心作用消失。5. 将该强心活性与静脉注射异丙肾上腺素的强心活性进行了比较。